| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.14 | 8e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.15 | 8e-05 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.14 | 8e-05 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.15 | 8e-05 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0001 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0001 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.17 | 0.0001 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0001 |